2015 Discharge: European Medicines Agency (EMA)

This procedure involves the European Parliament's review of how the European Medicines Agency (EMA) managed its budget during the 2015 financial year. The discharge process is a key part of democratic oversight, ensuring that the agency spent its funds transparently and in accordance with EU financial rules.

This decision affects the EMA's administration and financial management. A positive discharge confirms that the agency's accounts are accurate and its spending was justified.